ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0832

PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0672

Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0535

Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0577

Qualitative Review of Unsuccessful Pilot Study of Super-Utilizer Systemic Lupus Erythematosus (SLE) Patients Enrollment into Team Based Program to Improve Patient Outcomes

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0843

Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0844

Rab4A Regulates Glomerulonephritis and Tryptophan Metabolism in Sle1.2.3. Lupus-prone Mice via Recycling of CD98

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0651

Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0802

Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0803

Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0812

Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0556

Recent Use, Missed Doses and Discontinuation of Infliximab in New-users: Comparisons of Biosimilar and Originator Exposures

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0881

Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0563

Relation of Pain Sensitization to Isokinetic Knee Extension Torque: The MOST Study

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0694

Relationships Among Adherence and Patient Outcomes in a Cognitive Behavioral Plus Physical Activity Intervention for Older Adults with Osteoarthritis and Hypertension

Orthopedics, Low Back Pain, & Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 0686

Renal Evolution During the First Year of Urate-lowering Therapy According to Sonographic Joint Deposition: Data from the Lille-Alicante Inception Cohort

Metabolic & Crystal Arthropathies Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].